abstract |
The present invention relates to innovative pro-parvoviruses (PVs) expressing RNAi effectors, preferably shRNAs, directed against the CDK9 gene, which show improved anticancer activity. These new viruses are based on the ΔH-1PV silencer platform, which consists of the pro-parvovirus H-1PV, characterized by an in-frame deletion in the NS region (ΔH-1PV) and carries an shRNA expression cassette, where the expression of shRNA is regulated by H1 polymerization Enzyme III promoter control. In the present invention, the inventors aimed to use the ΔH-1 PV silencer to silence the CDK9 gene whose activity is normally deregulated in cancer cells and is known to contribute to tumorigenesis. The present invention also provides cells or organisms comprising the parvovirus. |